Mucosal vaccination with phage-displayed tumour antigens identified through proteomics-based strategy inhibits the growth and metastasis of 4T1 breast adenocarcinoma

Shadidi, Mohsen; Sørensen, Dag R.; Dybwad, Anne; Furset, Gro; Sioud, Mouldy

doi:10.3892/ijo.32.1.241

Cited by 14 publications

(18 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Shadidi et al [194] combined immunoprecipitation with a proteomic-based approach to uncover tumor antigens recognized by antibodies from patients with breast cancer. Serum antibodies from patients with breast cancer and from healthy individuals were immobilized on protein-G magnetic beads and used to immunoprecipitate potential tumor antigens from a breast carcinoma cell line.…”

Section: Strategies Developed To Identify Protein Ttas and Taasmentioning

confidence: 99%

Proteomics for development of vaccine

Adamczyk-Popławska

Markowicz

Jagusztyn-Krynicka

2011

Journal of Proteomics

View full text Add to dashboard Cite

Section: Strategies Developed To Identify Protein Ttas and Taasmentioning

confidence: 99%

Proteomics for development of vaccine

Adamczyk-Popławska

Markowicz

Jagusztyn-Krynicka

2011

Journal of Proteomics

View full text Add to dashboard Cite

“…The dependency of proliferating tumors on elevated levels of glucose metabolism has been known for many years, and increased levels of aldolase in malignancies was first identified in 1953 26,27. Since then, numerous publications have reported elevated levels of ALDOA in a variety of cancers, including breast, hepatocellular, and lung 28–32. Increased levels of ALDOA have also been associated with invasiveness and metastasis 33,34.…”

Section: Resultsmentioning

confidence: 99%

In silico Analysis of Combinatorial microRNA Activity Reveals Target Genes and Pathways Associated with Breast Cancer Metastasis

et al. 2011

View full text Add to dashboard Cite

This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.Aberrant microRNA activity has been reported in many diseases, and studies often find numerous microRNAs concurrently dysregulated. Most target genes have binding sites for multiple microRNAs, and mounting evidence indicates that it is important to consider their combinatorial effect on target gene repression. A recent study associated the coincident loss of expression of six microRNAs with metastatic potential in breast cancer. Here, we used a new computational method, miR-AT!, to investigate combinatorial activity among this group of microRNAs. We found that the set of transcripts having multiple target sites for these microRNAs was significantly enriched with genes involved in cellular processes commonly perturbed in metastatic tumors: cell cycle regulation, cytoskeleton organization, and cell adhesion. Network analysis revealed numerous target genes upstream of cyclin D1 and c-Myc, indicating that the collective loss of the six microRNAs may have a focal effect on these two key regulatory nodes. A number of genes previously implicated in cancer metastasis are among the predicted combinatorial targets, including TGFB1, ARPC3, and RANKL. In summary, our analysis reveals extensive combinatorial interactions that have notable implications for their potential role in breast cancer metastasis and in therapeutic development.

show abstract

“…Recently, oral immunization against 4T1 mammary adenocarcinoma has been reported. Several tumor antigens were expressed on the surface of the T7 phage and shown to trigger specific immune responses in BALB/c mice (Shadidi et al 2008). If this approach works in other cancer models it may become an effective strategy for mucosal cancer vaccines.…”

Section: Route Of Vaccinationmentioning

confidence: 99%

Cancer Vaccines. Any Future?

Myc

Gamian

Myc

2011

Arch. Immunol. Ther. Exp.

View full text Add to dashboard Cite

The idea that vaccination can be used to fight cancer is not new. Approximately 100 years ago, researchers attempted to stimulate a tumor-specific, therapeutic immune response to tumors by injecting patients with cells and extracts from their own tumors, or tumors of the same type from different individuals. During the last decade, great efforts have been made to develop immunotherapeutic approaches for the treatment of malignant diseases as alternatives to traditional chemo- and radiotherapy. A quintessential goal of immunotherapy in cancer is treatment with vaccines that elicit potent anti-tumor immune responses without side effects. In this article, we have attempted to review some of the most problematic issues facing the development of cancer vaccines. With the prospect of immunosuppression, an ill-designed cancer vaccine can be more harmful than a no-benefit therapy. We have noted that "immunoediting" and "immunodominance" are the premier setbacks in peptide-based vaccines and therefore it appears necessary not only to manipulate the activity of a vast number of principal components but also to finely tune their concentrations in time and space. In the face of all these quandaries, it is at least doubtful that any reliable anti-cancer vaccine strategy will emerge in the near future.

show abstract

Mucosal vaccination with phage-displayed tumour antigens identified through proteomics-based strategy inhibits the growth and metastasis of 4T1 breast adenocarcinoma

Cited by 14 publications

References 28 publications

Proteomics for development of vaccine

Proteomics for development of vaccine

In silico Analysis of Combinatorial microRNA Activity Reveals Target Genes and Pathways Associated with Breast Cancer Metastasis

Cancer Vaccines. Any Future?

Contact Info

Product

Resources

About